Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Lupus ; 30(11): 1819-1828, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-34569384

RESUMO

OBJECTIVES: Caveolin family proteins, including caveolin-1 (Cav-1), caveolin-2 (Cav-2), and caveolin-3 (Cav-3), are identified as the principal protein components of caveolae in mammalian cells. Circulating form of caveolin family proteins can be used as a good potential biomarker for predicting disease. METHODS: To investigate the clinical significance of the serological levels of caveolin family proteins in patients with systemic lupus erythematosus (SLE), we evaluated the soluble serum levels of caveolin family proteins in patients with SLE by enzyme-linked immunosorbent assay (ELISA) and assessed their associations with various known clinical variables. RESULTS: The major findings of our study are as follows: Cav-2 was not detected in serum of SLE patients and normal controls (NCs). Serum Cav-1 and Cav-3 levels were higher in SLE patients compared with NCs. There were no significant correlations between serum Cav-1 and Cav-3 levels and SLE disease activity. Further analysis showed that serum Cav-3 may be more valuable as a marker than serum Cav-1 in SLE patients. CONCLUSION: Serum levels of Cav-1 and Cav-3 might have a diagnostic role in patients with SLE. However, their predictive and prognostic value was not determined. Further studies are necessary to determine the potential clinical significance of these assays in SLE.


Assuntos
Biomarcadores , Caveolinas , Lúpus Eritematoso Sistêmico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Biomarcadores/sangue , Biomarcadores/metabolismo , Caveolina 1/biossíntese , Caveolina 1/sangue , Caveolina 3/biossíntese , Caveolina 3/sangue , Caveolinas/biossíntese , Caveolinas/sangue , Criança , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/metabolismo , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Adulto Jovem
2.
Int J Mol Sci ; 20(11)2019 May 29.
Artigo em Inglês | MEDLINE | ID: mdl-31146391

RESUMO

The noble gas helium (He) induces cardioprotection in vivo through unknown molecular mechanisms. He can interact with and modify cellular membranes. Caveolae are cholesterol and sphingolipid-enriched invaginations of the plasma-membrane-containing caveolin (Cav) proteins that are critical in protection of the heart. Mice (C57BL/6J) inhaled either He gas or adjusted room air. Functional measurements were performed in the isolated Langendorff perfused heart at 24 h post He inhalation. Electron paramagnetic resonance spectrometry (EPR) of samples was carried out at 24 h post He inhalation. Immunoblotting was used to detect Cav-1/3 expression in whole-heart tissue, exosomes isolated from platelet free plasma (PFP) and membrane fractions. Additionally, transmission electron microscopy analysis of cardiac tissue and serum function and metabolomic analysis were performed. In contrast to cardioprotection observed in in vivo models, the isolated Langendorff perfused heart revealed no protection after He inhalation. However, levels of Cav-1/3 were reduced 24 h after He inhalation in whole-heart tissue, and Cav-3 was increased in exosomes from PFP. Addition of serum to muscle cells in culture or naïve ventricular tissue increased mitochondrial metabolism without increasing reactive oxygen species generation. Primary and lipid metabolites determined potential changes in ceramide by He exposure. In addition to direct effects on myocardium, He likely induces the release of secreted membrane factors enriched in caveolae. Our results suggest a critical role for such circulating factors in He-induced organ protection.


Assuntos
Cardiotônicos/farmacologia , Caveolinas/metabolismo , Coração/efeitos dos fármacos , Hélio/farmacologia , Traumatismo por Reperfusão Miocárdica/tratamento farmacológico , Animais , Cardiotônicos/uso terapêutico , Cavéolas/efeitos dos fármacos , Cavéolas/metabolismo , Caveolinas/sangue , Caveolinas/genética , Células Cultivadas , Exossomos/efeitos dos fármacos , Exossomos/metabolismo , Hélio/uso terapêutico , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Mitocôndrias Cardíacas/efeitos dos fármacos , Mitocôndrias Cardíacas/metabolismo , Traumatismo por Reperfusão Miocárdica/prevenção & controle
3.
Biochim Biophys Acta ; 1858(8): 1891-903, 2016 08.
Artigo em Inglês | MEDLINE | ID: mdl-27137675

RESUMO

Platelets are small, anucleated cell fragments that activate in response to a wide variety of stimuli, triggering a complex series of intracellular pathways leading to a hemostatic thrombus formation at vascular injury sites. However, in essential hypertension, platelet activation contributes to causing myocardial infarction and ischemic stroke. Reported abnormalities in platelet functions, such as platelet hyperactivity and hyperaggregability to several agonists, contribute to the pathogenesis and complications of thrombotic events associated with hypertension. Platelet membrane lipid composition and fluidity are determining for protein site accessibility, structural arrangement of platelet surface, and response to appropriate stimuli. The present study aimed to demonstrate whether structural and biochemical abnormalities in lipid membrane composition and fluidity characteristic of platelets from hypertensive patients influence the expression of the Epithelial Sodium Channel (ENaC), fundamental for sodium influx during collagen activation. Wb, cytometry and quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) assays demonstrated ENaC overexpression in platelets from hypertensive subjects and in relation to control subjects. Additionally, our results strongly suggest a key role of ß-dystroglycan as a scaffold for the organization of ENaC and associated proteins. Understanding of the mechanisms of platelet alterations in hypertension should provide valuable information for the pathophysiology of hypertension.


Assuntos
Plaquetas/metabolismo , Canais Epiteliais de Sódio/sangue , Regulação da Expressão Gênica , Hipertensão/sangue , Fluidez de Membrana , Sódio/sangue , Idoso , Aldosterona/sangue , Plaquetas/ultraestrutura , Estudos de Casos e Controles , Caveolina 1/farmacologia , Caveolinas/sangue , Distroglicanas/antagonistas & inibidores , Distroglicanas/biossíntese , Distroglicanas/sangue , Distroglicanas/genética , Canais Epiteliais de Sódio/biossíntese , Canais Epiteliais de Sódio/genética , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Hidrocortisona/sangue , Transporte de Íons , Masculino , Pessoa de Meia-Idade , Interferência de RNA , RNA Interferente Pequeno/genética
4.
Anticancer Res ; 29(7): 2589-600, 2009 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-19596933

RESUMO

Specificity of PSA has been enhanced by using molecular forms of PSA and free PSA (fPSA) such as percent free PSA (% fPSA), proPSA, intact PSA or BPHA and/or new serum markers. Most of these promising new serum markers like EPCA2 or ANXA3 still lack confirmation of outstanding initial results or show only marginal enhanced specificity at high sensitivity levels. PCA3, TMPRSS2-ERG, and other analytes in urine collected after digital rectal examination with application of mild digital pressure have potential to preferentially detect aggressive PCa and to decrease the rate of unnecessary repeat biopsies. The combination of these new urinary markers with new and established serum markers seems to be most promising to further increase specificity of tPSA. Multivariate models e.g. artificial neural networks (ANN) or logistic regression (LR)-based nomograms have been recently developed by incorporating these new markers in several studies. There is generally an advantage to including new markers and clinical data as additional parameters to PSA and % fPSA within ANN and LR models. The results and unexpected pitfalls of these studies are shown.


Assuntos
Biomarcadores Tumorais/sangue , Neoplasias da Próstata/diagnóstico , Antígenos de Neoplasias/sangue , Caveolinas/sangue , Fator 15 de Diferenciação de Crescimento/sangue , Humanos , Calicreínas/sangue , Masculino , Análise Multivariada , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/sangue , Somatomedinas/metabolismo
5.
Oncol Nurs Forum ; 30(5): 741-2, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12966928

Assuntos
Neoplasias/tratamento farmacológico , Neoplasias/enfermagem , Anti-Inflamatórios não Esteroides/uso terapêutico , Biomarcadores Tumorais/sangue , Neoplasias da Mama/genética , Neoplasias da Mama/imunologia , Neoplasias da Mama/patologia , Neoplasias da Mama/prevenção & controle , Carcinoma de Células Renais/sangue , Carcinoma de Células Renais/patologia , Caveolina 1 , Caveolinas/sangue , Neoplasias do Colo/prevenção & controle , Ciclo-Oxigenase 2 , Esquema de Medicação , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/uso terapêutico , Feminino , Óleos de Peixe/química , Óleos de Peixe/uso terapêutico , Humanos , Fator de Crescimento Insulin-Like I/metabolismo , Isoenzimas/administração & dosagem , Isoenzimas/antagonistas & inibidores , Isoenzimas/uso terapêutico , Neoplasias Renais/sangue , Neoplasias Renais/patologia , Masculino , Proteínas de Membrana , Neoplasias/sangue , Neoplasias/prevenção & controle , Proteínas Nucleares/metabolismo , Valor Preditivo dos Testes , Prostaglandina-Endoperóxido Sintases/administração & dosagem , Prostaglandina-Endoperóxido Sintases/uso terapêutico , Neoplasias da Próstata/sangue , Neoplasias da Próstata/química , Neoplasias da Próstata/etnologia , Neoplasias da Próstata/patologia , Proteômica/tendências , Medição de Risco/estatística & dados numéricos , Sociedades Médicas , Tamoxifeno/administração & dosagem , Tamoxifeno/uso terapêutico , Transativadores/metabolismo , Estados Unidos
6.
Clin Cancer Res ; 9(10 Pt 1): 3653-9, 2003 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-14506154

RESUMO

PURPOSE: Caveolin-1 (cav-1), the major protein component of caveolae, plays an important role in multiple signaling pathways, molecular transport, and cellular proliferation and differentiation. The specific functions of cav-1/caveolae are highly cell and context dependent. We have previously shown that cav-1 expression is increased in metastatic human prostate cancer and that cav-1 cellular protein expression is predictive of recurrence of the disease after radical prostatectomy. Recently, we reported that cav-1 is secreted by androgen-insensitive prostate cancer cells, and we detected, by Western blotting, cav-1 in the high-density lipoprotein(3) fraction of serum specimens from patients with prostate cancer. EXPERIMENTAL DESIGN: Using rabbit polyclonal antibodies with specificity for cav-1, we developed a direct sandwich immunoassay for the determination of cav-1 in serum. A recombinant human cav-1 fusion protein was overexpressed and purified from 293 PE cells and used as a calibrator. RESULTS: The assay was highly specific and had a minimum detection limit of 0.017 ng/ml (mean + 3 SD of zero calibrator) and measuring range of up to 200 ng/ml. Intra-assay coefficient of variation was 2.29-6.74% and inter-assay coefficient of variation was 2.81-6.43% over the serum concentration tested 0.04-31.89 ng/ml. The recovery limit of cav-1 by the assay was 89.55-100.28%. The median serum cav-1 level in 102 prostate cancer patients with clinically localized disease (0.463 ng/ml) was significantly higher than 81 healthy control men (0.324 ng/ml; P = 0.0446, Mann-Whitney test) or 107 men with benign prostatic hyperplasia (0.172 ng/ml; P = 0.0317, Mann-Whitney test). CONCLUSIONS: Our results indicate that serum cav-1 has the power to differentiate between prostate cancer and benign prostatic hyperplasia patients and the potential to be an important biomarker for prostate cancer. Additional studies to test the potential of serum cav-1 as a diagnostic and/or prognostic marker in prostate cancer are warranted.


Assuntos
Biomarcadores Tumorais , Caveolinas/sangue , Ensaio de Imunoadsorção Enzimática/métodos , Imunoensaio/métodos , Neoplasias da Próstata/sangue , Idoso , Animais , Anticorpos/química , Western Blotting , Calibragem , Caveolina 1 , Linhagem Celular , Relação Dose-Resposta a Droga , Humanos , Masculino , Pessoa de Meia-Idade , Hiperplasia Prostática/patologia , Neoplasias da Próstata/diagnóstico , Coelhos , Proteínas Recombinantes/química , Sensibilidade e Especificidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...